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Introduction: The preoperative phase is an important period in which to prevent surgical
site infections (SSIs). Prophylactic antibiotic use helps to reduce SSI rates, leading to
reductions in hospitalization time and cost. In clinical practice, besides effectiveness
and safety, the selection of prophylactic antibiotic agents should also consider the
evidence with regard to costs and microbiological results. This review assessed the
current research related to the use of antibiotics for SSI prophylaxis from an economic
perspective and the underlying epidemiology of microbiological findings.
Methods: A literature search was carried out through PubMed and Embase databases
from 1 January 2006 to 31 August 2017. The relevant studies which reported the use
of prophylactic antibiotics, SSI rates, and costs were included for analysis. The causing
pathogens for SSIs were categorized by sites of the surgery. The quality of reporting on
each included study was assessed with the “Consensus on Health Economic Criteria”
(CHEC).
Results: We identified 20 eligible full-text studies that met our inclusion criteria, which
were subsequently assessed, studies had in a reporting quality scored on the CHEC list
averaging 13.03 (8–18.5). Of the included studies, 14 were trial-based studies, and the
others were model-based studies. The SSI rates ranged from 0 to 71.1% with costs
amounting to US$480-22,130. Twenty-four bacteria were identified as causative agents
of SSIs. Gram negatives were the dominant causes of SSIs especially in general surgery,
neurosurgery, cardiothoracic surgery, and obstetric cesarean sections.
Conclusions: Varying results were reported in the studies reviewed. Yet, information
from both trial-based andmodel-based costing studies could be considered in the clinical
implementation of proper and efficient use of prophylactic antibiotics to prevent SSIs and
antimicrobial resistance.
Keywords: antibiotic prophylaxis, surgical wound infection, bacterial pathogens, health economic and outcome
research, costs and cost analysis, systematic review
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INTRODUCTION
Surgical site infections (SSIs) reflect an important complication
inmodern healthcare (Berrios-Torres et al., 2017). As the surgical
site is a potential port entry for exogenous organisms, it poses an
immediate threat to the body and infections lead to prolonged
wound healing (Mangram et al., 1999; Berrios-Torres et al., 2017).
The preoperative phase is considered the most crucial period of
a surgical procedure in which the goal is to reduce the bacterial
load surrounding the incision area. Using antibiotics prior to
surgical incision is considered to be effective in preventing
SSIs, which are among the most common preventable post-
surgery complications involving healthcare-associated infections
(HAIs) (Mangram et al., 1999; Umscheid et al., 2011). A
parenteral prophylaxis agent spectrum with corresponding
potential bacteria on particular sites of surgery has been
recommended recently to reduce SSI rates efficiently (Berrios-
Torres et al., 2017). In contrast, some preoperative procedures,
such as hair removal and mechanical bowel preparation are
considered today to be inefficient at reducing SSIs (Leaper et al.,
2008; Anderson et al., 2014).
In the US, SSIs were identified in ∼1.9% of 849,659 surgical
procedures in 43 states from 2006 to 2008 (Mu et al., 2011). The
economic burden of SSIs should be taken into account in the
use of prophylactic antibiotics. In the US in 2010, more than 16
million surgical procedures were performed (CDC, 2010). The
annual costs of SSIs amounted to approximately US$3 billion
in 2012, having increased from an estimated US$1.6 billion cost
attributable to SSIs in 2005 (de Lissovoy et al., 2009; Zimlichman
et al., 2013). In low-and middle-income countries, SSI rates
doubled from 5.6 to 11.8 in 100 surgical patients between 1995
and 2008 (Allegranzi et al., 2011). The reporting of cost and
effectiveness in infectious disease presents a crucial topic, ideally
supported by updated antimicrobial resistance data. Notably,
economic analyses can be differentiated into trial-based—directly
linked to a trial that often also already comprises part of the
economic variables—and model-based studies with information
gathered from various sources and integrated into a health-
economic model. The aim of this study is to present recent
evidence from trial-based and model-based costing studies and
analyze the methodologies used in economic evaluations of
prophylactic antibiotics in SSI prevention. In addition, the study
comprehensively analyzes the quality of the included studies and
local epidemiology of pathogen-causing SSIs.
MATERIALS AND METHODS
This review was registered in PROSPERO with number
CRD42017076589. This study was designed according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (Moher et al., 2009).
Search Strategy
We searched the updated relevant evidence from PubMed and
EMBASE databases. To consider changes over time in inflation
rates, value of money, and patterns in microbial causes of
SSIs and contemporary antimicrobial susceptibility, we initially
searched a 10-year period (2006-2016) which we later updated
to 31 August 2017. The search used search terms or phrases
represented in Medical Subject Headings (MeSH) with the
operator “tiab” for PubMed. Subsequently, the terms or phrases
used in PubMed were translated to the EMBASE database by
using strings and the symbols “ab,ti.” To refine the result, we
employed a search strategy using the Boolean operator “OR”
within sequences of terms with close or similar meanings and
“AND” for one or more sequences of terms which contained
completely different meanings. Whole terms and phrases for
either PubMed or Embase were identified by two persons (AKRP
and KS) who dealt with the search strategy.
Study Selection
Trial-based and model-based studies that examined the clinical
benefits and costs related to the uses of prophylactic antibiotics
for SSIs were considered as eligible for inclusion in this review.
Therefore, we developed criteria to identify the eligible studies
which contained economic analysis and followed the defined
PICO-approach (Patient or Problem, Intervention, Control, and
Outcomes). Concerning the patient (P), patients undergoing
all types of surgical procedures were included. There was no
restriction on age or gender. For both the intervention (I) and
comparison (C), this review included studies concerning the
utilization of antibiotic prophylaxis administered intravenously,
orally, or locally to prevent SSI. Other terms of post-surgical
infections such as wound infections and sternal wound infections
(SWIs) were included. We excluded studies mainly evaluating
comparisons of the use of antiseptic, pharmaceutical care
interventions or guideline adherence issues. For the outcomes
(O), we included studies evaluating both SSI rates and cost.
Eventually, the integrated results of searches were restricted to
English full-text studies. Studies issued as commentary, editorials,
research protocols or reviews were excluded.
Data Extraction
Two authors (AKRP and DS) independently assessed all included
papers. Any disagreements between those authors were discussed
with a third author (JWD) until the discrepancies were
resolved by consensus. Fields of the extracted data included the
authorship, year of publication, journal, country, type of surgery,
wound categorization, gender, age, sample size, outcomes,
prophylactic antibiotics, SSI rates, timing for the prophylactic
strategy, follow-up, and length of stay. To address the outcome
from a microbiology perspective, we extracted the pathogens
based on the sites of the surgery, antimicrobial susceptibility,
and their resistance rates. Furthermore, we grouped the types of
SSIs based on the definitions and classifications of SSIs from the
Centers for Disease Control and Prevention (CDC) (Horan et al.,
1992).
Cost Analysis and Data Synthesis
We categorized the methodology on the health-economic
analyses and outcomes for each eligible study according
to four approaches (Drummond et al., 2015). The first
was cost minimization analysis (CMA), which represents a
straightforward method to identify the costs of different
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alternatives with estimated equal health outcomes of the
interventions. The second was cost effectiveness analysis (CEA)
where the outcomes are expressed in a natural unit of health
including the number of patients with clinical improvement of
an infectious disease or life-years gained. The third was a cost
benefit analysis (CBA), in which the interventions are made
comparable in terms of benefit and cost with all aspects being
expressed in financial units. The last was cost utility analysis
(CUA), which includes utility estimates potentially representing
preferences for health outcomes, reporting quality-adjusted life
years (QALYs) or alternatively disability-adjusted life years
(DALYs). Furthermore, for the cost types, we took into account
cost perspectives with components of (1) direct costs such as
costs for prophylactic antibiotics, hospitalization, side-effects,
and antimicrobial resistance, and (2) indirect costs including
costs of loss of productivity. We made costs comparable among
individual studies using currency conversions to US$ and
corrections for inflation rates. We calculated inflation rates based
on the 2015 annual GDP growth index in the World DataBank
for each respective country (The World Bank, 2015). If the
individual article did not state the actual year for the cost
analyses, we made the assumption that the year of the cost
estimate was the same as the last year of data collection.
Quality Assessments
We used the Consensus on Health Economic Criteria (CHEC)
list to assess the quality of reporting of the health economic
outcomes, including potential bias in individual studies (Evers
et al., 2015). This CHEC instrument comprises a 19-item list
that relates to study design (4 items), time horizon, actual
perspective, cost evaluation (5 items), outcome measurements
(3 items), discounting, conclusion, generalization, conflict of
interest, and ethical issues (Husereau et al., 2013). These items
can be conceived to reflect minimum requirements for health
economic papers. We scored one point for “yes,” indicating an
item to be satisfied. Marks of “unclear” and “no” were scored
half a point and zero respectively. Therefore, the minimum and




This review initially identified a total of 644 and 1,417 articles
from PubMed and Embase respectively. A comprehensive listing
of the searches in both PubMed and Embase can be found in
Tables S1, S2. After removing duplications, we screened 1,529
titles and abstracts. Subsequently, we excluded 1,321 articles
for the reasons listed in the Materials and Methods section.
Eventually, we assessed 208 eligible full-text studies of which
we excluded 188 because of being reviews, having incomplete
data related to costs and lack of presenting on the outcomes of
prophylactic antibiotic uses and SSI incidence (Table S3). A total
of 20 articles remained according to the inclusion criteria and
were extracted systematically for further analyses (Chaudhuri
et al., 2006; Dhadwal et al., 2007; Alekwe et al., 2008;Wilson et al.,
FIGURE 1 | Flow chart of search strategy on identifying eligible and included studies with standard report of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA).
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2008; Kosus et al., 2010; Patil et al., 2011; Courville et al., 2012;
Gulluoglu et al., 2013; Merollini et al., 2013; Emohare et al., 2014;
Matsui et al., 2014; Theologis et al., 2014; Joshi et al., 2016). A
flow chart of the search is shown in Figure 1.
General Characteristics of Included
Studies
The general characteristics of the included studies are presented
in Table 1. For the further characteristics of the 20 included
studies, the most studies came from North-America (Wilson
et al., 2008; Courville et al., 2012; Emohare et al., 2014; Matsui
et al., 2014; Singh et al., 2014; Theologis et al., 2014; Graves et al.,
2016; Lewis et al., 2016), followed by Asia (Kosus et al., 2010;
Patil et al., 2011; Gulluoglu et al., 2013; Ozdemir et al., 2016),
Europe (Chaudhuri et al., 2006; Dhadwal et al., 2007; Elliott et al.,
2010; Joshi et al., 2016), Africa (Alekwe et al., 2008; El-Mahallawy
et al., 2013), Australia (Merollini et al., 2013), and South America
(Ceballos et al., 2017). The reviewed articles concerned 14 trial-
based studies (Chaudhuri et al., 2006; Dhadwal et al., 2007;
Alekwe et al., 2008; Wilson et al., 2008; Kosus et al., 2010; Patil
et al., 2011; El-Mahallawy et al., 2013; Gulluoglu et al., 2013;
Emohare et al., 2014; Matsui et al., 2014; Theologis et al., 2014;
Joshi et al., 2016; Lewis et al., 2016; Ozdemir et al., 2016) and 6
model-based studies (Elliott et al., 2010; Courville et al., 2012;
Merollini et al., 2013; Singh et al., 2014; Graves et al., 2016;
Ceballos et al., 2017). Table 2 presents the baseline characteristics
of the included studies. Moreover, six trial-based studies were
performed as a formal randomized controlled trial (RCT) with
the number of patients involved in the studies ranging between 50
TABLE 1 | General characteristics of the 20 included articles.






North America 8 (40)





Obstetric gynecology 2 (10)
Oncology 3 (15)
Orthopedic 6 (30)





CMA, cost minimization analysis; CBA, cost benefit analysis; CEA, cost effectiveness
analysis; CUA, cost utility analysis.
and 1,196 (Chaudhuri et al., 2006; Alekwe et al., 2008; Kosus et al.,
2010; El-Mahallawy et al., 2013; Gulluoglu et al., 2013; Matsui
et al., 2014).
Antibiotic Prophylaxis in General Surgery
Five included studies analyzed the cost and effectiveness of
antibiotic prophylaxis in general surgery (Chaudhuri et al., 2006;
Wilson et al., 2008; Matsui et al., 2014; Singh et al., 2014; Ozdemir
et al., 2016). The types of surgery were pilonidal sinus excision
(Chaudhuri et al., 2006), elective colorectal surgery (Wilson
et al., 2008; Ozdemir et al., 2016), laparoscopic cholecystectomy
(Matsui et al., 2014), and general abdominal surgery (Singh
et al., 2014). The included studies indicated that new generation
antibiotics generated economic benefit in SSI prevention. An
observational study reported that the use of ertapenem in elective
colorectal surgery achieved cost savings of roughly US$2,200
per patient compared with cefotetan (Wilson et al., 2008). The
secondary costs due to selection regarding resistance were not
taken into account in this study and would need to be assessed
in future studies. Another study showed that triclosan-coated
sutures seemed to be cost saving and effective at reducing SSI
rates from the hospital, payer, and societal perspectives (Singh
et al., 2014). However, no long-term data on tissue-toxicity and
possible triclosan-induced inflammatory response was included
in this study. In addition, single prophylactic antibiotics and both
oral or intravenous administration were demonstrated to have a
positive impact on reducing SSI rates andmedical costs in general
surgery (Chaudhuri et al., 2006; Matsui et al., 2014).
Antibiotic Prophylaxis in Orthopedic
Surgery
Various studies modeled economic and clinical impacts from
the societal and healthcare perspectives of patients undergoing
total hip arthroplasty (THA), total knee arthroplasty (TKA),
and lower limb amputation (Elliott et al., 2010; Courville
et al., 2012; Merollini et al., 2013; Graves et al., 2016; Ceballos
et al., 2017). Economic analysis on the implementation of the
use of nasal mupirocin to prevent deep SSI of Staphylococcus
aureus in THA and TKA showed that mupirocin was more
cost-effective compared to non-preoperatively administered
mupirocin with incremental cost-effectiveness ratios (ICERs)
at US$380.09/QALY and US$517.16/QALY for THA and TKA
respectively (Courville et al., 2012). Vancomycin has also been
taken into account as an intra-wound antibiotic, with SSI rates
of 3 and 11% were identified in the group with and without 2 g
vancomycin powder respectively. Clinically and economically,
these percentages were considered to reflect a significant impact
with cost savings of US$2,762 per operative procedure at day 90
post-surgery (Theologis et al., 2014). Furthermore, two studies
addressed that prophylactic intervention was dominant over no
prophylactic antibiotics on SSI rates and cost reductions in total
hip arthroplasty and lower limb amputation (Merollini et al.,
2013; Ceballos et al., 2017).
Antibiotic Prophylaxis in Neurosurgery
Two cost-minimization studies on neurosurgery concerned
intra-wound vancomycin and Prolonged Prophylactic Systemic
Frontiers in Pharmacology | www.frontiersin.org 4 July 2018 | Volume 9 | Article 776
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Antimicrobials (PPSAs) (Emohare et al., 2014; Lewis et al., 2016).
Firstly, a cohort study, for the purpose of reimbursement to
the hospital for SSI costs, evaluated the cost savings achieved
by adding intra-wound vancomycin powder as prophylactic
therapy to standard intravenous cefazolin in patients who
underwent spinal surgery. No SSIs were reported in patients
who received intra-wound vancomycin, whereas seven out of
207 patients who were given only cefazolin developed SSIs
at a cost of US$2,879 per patient (Emohare et al., 2014).
Secondly, a retrospective study looked into the duration of
prophylactic antibiotic use in cranial surgery and subdural or
subgaleal drains. Continuous prophylactic antibiotics or PPSAs
were considered costly compared with non-PPSA treatment in
the operation, which saved US$93,195 per patient (Lewis et al.,
2016).
Antibiotic Prophylaxis in Cardiothoracic
Surgery
Two included RCTs and an observational study evaluated the
clinical and economic impact of antibiotics for prevention
of SWIs in coronary surgery. First, one RCT study reported
that the use of triple antibiotics of rifampicin gentamicin,
and vancomycin for SSI prophylaxis could reduce the total
cost of treatment by US$4,521 per patient compared to single
prophylaxis of cefuroxime (Dhadwal et al., 2007). Second,
an observational study on Gentamicin-impregnated Collagen
Sponges (GCS) to prevent SSIs in cardiac surgery noted a unit
cost of GCS of roughly US$129 per patient. Nevertheless, in their
cost analysis, they remarked that GCS provided no economic
benefit in reducing SSI incidence by 50% SSI in a 2-year period
(Joshi et al., 2016).
Antibiotic Prophylaxis in Obstetric and
Gynecological Surgery
In obstetric and gynecological surgery, two included RCT-
based studies analyzed SSI incidence and performed an
economic impact analysis of ceftriaxone prophylactic in delivery
through cesarean section. The first RCT compared single-
dose prophylactic ceftriaxone to a triple drug combination
of ampicillin/cloxacillin, gentamicin, and metronidazole.
Notwithstanding the economic benefit of a single dose of
ceftriaxone compared with the combination regimen, the SSI
rates were between 7% with ceftriaxone and 8% with the triple
drug treatments (Alekwe et al., 2008). The second RCT was
carried out on the implementation of subcutaneous rifamycin
as add-on therapy for prophylactic ceftriaxone. Twelve allocated
subjects for the standard prophylactic were followed up with
SSI, and in these cases, the total cost related to SSI treatment
amounted to US$483 per patient. On the other hand, no
patient developed SSI by the end of the follow-up period in the
intervention group (Kosus et al., 2010).
Antibiotic Prophylaxis in Oncology Surgery
Three included studies concerned different operative procedures
in oncology surgery for malignancies of the breast, head-neck,
bladder, stomach, colon, and rectum (Patil et al., 2011; El-
Mahallawy et al., 2013; Gulluoglu et al., 2013). An observational
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study in surgery for head and neck cancer by Patil et al.
(2011) conveyed that no significant difference was indicated
in the total cost between single and combination antibiotics.
On the other hand, an RCT study on breast cancer surgery
by Gulluoglu et al. (2013) presented that antibiotic prophylaxis
with intravenous ampicillin-sulbactam was more cost saving and
effective compared to no prophylaxis, resulting in a 9% reduction
in the SSI rate and a cost reduction of US$11 per patient.
Moreover, another RCT on abdominal cancer by El-Mahallawy
et al. (2013) indicated cost savings with the combination of
penicillin and gentamicin over using clindamycin and amikacin.
Table 3 compares the included studies on reporting cost analysis.
In addition, the SSI rates and the cost ranges of each surgical
procedure are presented in Table 4.
Timing of Antibiotic Prophylactic
Interventions
The starting time of antibiotics in prophylactic administrations
was different ranging from an hour before the surgical procedure
to the time of skin incision. Five studies explicitly stated at
the time of starting the prophylactic antibiotics (Chaudhuri
et al., 2006; Dhadwal et al., 2007; Wilson et al., 2008; Matsui
et al., 2014; Ozdemir et al., 2016). Chaudhuri et al. (2006)
and Wilson et al. (2008) reported the administration of the
agents 30min preoperatively for cefuroxime, metronidazole,
and cefotetan. Rifampicin in the study conducted by Dhadwal
et al. (2007) was administered orally an hour before incision
and followed by vancomycin post-induction of anesthesia.
Additionally, intravenous cefazolin sodium was injected before
skin incision. Elongation of antibiotic prophylaxis was also
expounded in the studies, for instance, being explicitly analyzed
by Chaudhuri et al. (2006), Dhadwal et al. (2007), and Alekwe
et al. (2008).
Reports of the Microorganisms Causing
SSI
From 7 included studies, this review generated a list of 24 bacteria
that were reported as causing SSIs at the site of surgery on the
cranium, thorax, abdomen, and thoracolumbar spine (Dhadwal
et al., 2007; Kosus et al., 2010; El-Mahallawy et al., 2013;
Gulluoglu et al., 2013; Theologis et al., 2014; Lewis et al., 2016;
Ozdemir et al., 2016). The predominant species that have been
reported to be found for SSIs were gram-negative bacteria. The
most common pathogen reported among studies was Escherichia
coli isolates, accounting for 6.7–50% of incidence in general
surgery, orthopedic, cardiothoracic surgery, and cesarean section
(Dhadwal et al., 2007; Kosus et al., 2010; Theologis et al.,
2014; Ozdemir et al., 2016). More importantly, S. aureus was
the second most prevalent which was dominant among gram-
positives causing SSIs (Dhadwal et al., 2007; El-Mahallawy et al.,
2013; Gulluoglu et al., 2013; Ozdemir et al., 2016). Anaerobic
bacteria were also reported, with an isolated case of Bacillus
fragilis as a rare bacteria, accounting for ∼13% of the SSI causes
among cesarean section procedures (Kosus et al., 2010). We
compiled the results of the pattern of bacterial causation of SSIs
in Table 5.
Quality Assessments of the Included
Studies
The range of CHEC scores in the included studies was from
a low of 8 to a high of 18.5 (Dhadwal et al., 2007; Graves
et al., 2016). The quality assessment scores of studies regarding
general surgery ranged from 10 to 12 (Chaudhuri et al., 2006;
Wilson et al., 2008; Matsui et al., 2014; Singh et al., 2014;
Ozdemir et al., 2016). Among studies on orthopedic surgery and
neurosurgery, the quality ranged between 12 and 18.5 (Elliott
et al., 2010; Courville et al., 2012; Merollini et al., 2013; Emohare
et al., 2014; Theologis et al., 2014; Graves et al., 2016; Lewis
et al., 2016; Ceballos et al., 2017). Two cardiothoracic studies
scored 8 and 11.5 points for CHEC items (Dhadwal et al., 2007;
Joshi et al., 2016). Two obstetric and gynecological studies were
scored at 10.5 and 11 (Alekwe et al., 2008; Kosus et al., 2010).
Furthermore, two oncologic surgery studies obtained quality
scores of 9.5 and 12.5 (Patil et al., 2011; El-Mahallawy et al.,
2013; Gulluoglu et al., 2013). From the CHEC items, concerns
mostly related to incremental analysis and sensitivity analysis.
The quality assessments of each article are reported in Table 6.
DISCUSSION
Guidance for the reporting of economic and clinical studies in the
specific field of infectious disease and antibiotic use is urgently
needed. Choosing the use of prophylactic antibiotics especially
for SSIs should take into account the local epidemiological data
of the pathogens and antimicrobial susceptibility. The microbial
etiology of SSIs and antibiotic resistance are completely missing
from reports of the mid-and long-term economic impact of
antibiotic use. For the economic part, in general, the minimum
requirements of the established CHEC checklist can assist in the
reporting of economic studies. On the other hand, the different
checklist from the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement has been performed to
assess the quality of economic study (Evers et al., 2005; Husereau
et al., 2013). However, the CHEERS checklist only considers the
completeness of reporting and does not evaluate the quality.
The other checklist which was developed by Caro et al. (2012)
was merely to conceptualize for model-based studies. Hence, the
CHEC checklist is more applicable and appropriate for quality
assessment in this review.
The diversity in definition of SSIs in terms of the period
to identify the SSIs potentially generates under-reporting of
the diseases’ occurrence. Despite the definition from the CDC
(Horan et al., 1992), other definitions were addressed by Peel and
Taylor (1991) from the Surgical Infections Society Study Group
(SIGS) and Ayliffe et al. (1993) from the National Prevalence
Survey (NPS) which considered grouping wound infection based
on the cause of infection, the time of appearance, and the severity
of infection. For the time of the appearance of infection, they
divided this into three categories, namely early, intermediate,
and late based on whether the infection appeared in a 30-
day period, in a period of between 1 and 3 months, and over
3 months post-surgery, respectively. By these definitions, the
reimbursement for the cost be accurately predicted especially in
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TABLE 3 | Comparisons of included studies on reporting of cost index year, cost analysis method, cost perspective, and costs (adjusted to US$ at 2015 prices).
Study, year of
publication
Cost index year Cost analysis
method
Cost perspective Adjusted costs in US$
GENERAL SURGERY
Chaudhuri et al., 2006 2006 CMA NA Total cost in group with a single-dose Metronidazole: US$11.53 per patient
Total cost for SSI complications: US$813.25 per patient
Wilson et al., 2008 2005 CMA NA Cost per dose of ertapenem: US$47.86 per patient
Cost per dose of cefotetan: US$29.78 per patient
Direct medical cost in group with etapenem prophylaxis: US$16,433.89 per
patient
Direct medical cost in group with cefotetan prophylaxis: US$18,812.66 per
patient
Matsui et al., 2014 2013 CMA NA Cost for antibiotics in group with cefazolin: US$25.73 per patient;
Cost for antibiotics in group without prophylactic: US$8.37 per patient;
Direct medical cost in group with cefazolin: US$791.59 per patient;
Direct medical cost in group without prophylactic: US$859.58 per patient.
Singh et al., 2014 2013 CMA Healthcare, payer
and societal
perspective
For 15% SSI risk, triclosan-coated suture saved:
- US$4,232.27 – 14,394.25 per patient (Hospital perspective)
- US$4,256.99 – 14,725.91 per patient (Payer perspective)
- US$41,330.81 – 54,841.32 per patient (Societal perspective)
Ozdemir et al., 2016 2016 CMA NA Total hospital cost:
- In group with cefazolin and metronidazole intravenously plus metronidazole
and gentamicin orally: US$2,699 per patient
- In group with cefazolin and metronidazole intravenously: US$4,411 per
patient
ORTHOPEDIC
Elliott et al., 2010 2005 CUA Societal perspective Total cost per QALY for SSI-treatments
- In group with vancomycin prophylactic: US$1,417.78/QALY
- In group with cephalosporin prophylactic: US$1,418.01/QALY
- In group with combination prophylactic: US$1,421.48/QALY
Courville et al., 2012 2005 CEA Societal perspective Average cost per QALY:
Total hip arthroplasty:
- Treated with mupirocin: US$34,990.65/QALY
- Treated with mupirocin and screened positive for S.aureus:
US$35,308.54/QALY
- Without mupirocin: US$35,370.74/QALY
Total knee arthroplasty:
- Treated with mupirocin: US$41,368.18/QALY
- Treated with mupirocin and screened positive for S.aureus:
US$41,775.92/QALY
- Without mupirocin: US$41,885.34/QALY
Merollini et al., 2013 2011 CEA Healthcare
perspective
ICER non-prophylactic compared with prophylactic antibiotics:
US$9,917.14/QALY-lost
Add-on antibiotic-impregnated prophylaxis saving
US$4,164.81/QALY-gained
Theologis et al., 2014 2009 CMA NA Cost for vancomycin powder: US$38.30 per operative procedure
Total cost in group with vancomycin powder: US$78,745.18 per operation
Total cost in group without vancomycin powder: US$71,514.31 per
operation
Cost saving using vancomycin powder: US$276,174.26 per 100 operative
procedures
Graves et al., 2016 2012 CUA Healthcare
perspective
With the reference of non-systemic antibiotics+ plain cement+ conventional










Frontiers in Pharmacology | www.frontiersin.org 9 July 2018 | Volume 9 | Article 776
Purba et al. Cost Analysis in the Use of Prophylactic Antibiotics
TABLE 3 | Continued
Study, year of
publication
Cost index year Cost analysis
method
Cost perspective Adjusted costs in US$
Ceballos et al., 2017 2014 CEA Healthcare
perspective
Incremental cost between non-prophylactic and prophylactic group:
US$1,245.83 per patient
NEUROSURGERY
Emohare et al., 2014 2012 CMA NA Cost for intra-wound vancomycin: US$12.46 per patient
Direct medical cost in group without intra-wound vancomycin: US$2,879.02
per patient
Lewis et al., 2016 2015 CMA NA Direct cost for PPSAs: US$887.50 per patient
Cost saving for Non-PPSAs: US$93,194.63 per patient
CARDIOTHORACIC SURGERY
Dhadwal et al., 2007 2004 CMA NA Cost for prophylactic antibiotics:
- In the group with single prophylactic antibiotic: US$540.18 per patient
- In the group with combination prophylactic antibiotics: US$425.95 per
patient
Total hospital costs:
- In the group with single prophylactic antibiotic: US$22,130.53 per patient
- In the group with combination prophylactic antibiotics: US$17,609.24 per
patient
Joshi et al., 2016 2013 CMA NA Median cost without SSI: US$15,502.72 per patient
Median additional cost for SSI treatments: US$7,835.59 per patient
Cost for the GCS: US$128.96 per patient
Total annual additional costs in reducing SSI incidence by 50%
- Without GCS: US$70,523.90 per patient
- With GCS: US$115,924.59 per patient
OBSTETRIC GYNECOLOGICAL SURGERY
Elliott et al., 2010 2008 CMA NA Costs for antibiotics:
- In group with single prophylactic antibiotic: US$10.61 per patient
- In group with combination prophylactic antibiotics: US$16.52 per patient
Courville et al., 2012 2007 CMA NA The price of rifamycin: US$1.58 per patient
Mean cost for SSI treatments: US$482.59 per patient
ONCOLOGIC SURGERY
Patil et al., 2011 2007 CMA NA Costs in group with single antibiotic:
- Prophylactic antibiotic costs: US$7.22 per patient
- Post-surgical antibiotic costs: US$79.76 per patient
- Total antibiotics costs: US$86 per patient
Costs in group with combination of prophylactic antibiotics:
- Prophylactic antibiotic costs: US$12.13 per patient
- Post-surgical antibiotics costs: US$82.79 per patient
- Total antibiotics costs: US$94.92 per patient
Gulluoglu et al., 2013 2010 CMA NA Costs for SSI treatments:
- In group with prophylactic antibiotics: US$9.18 per patient
- In group without prophylactic antibiotics: US$21.93 per patient
El-Mahallawy et al.,
2013
2013 CMA NA Direct cost in group with penicillin G sodium and gentamicin: US$3.26 per
patient
Direct cost in group with clindamycin and amikacin: US$17.39 per patient
CMA, cost minimization analysis; GCS, Gentamicin collagen sponges; ICER, incremental cost-effectiveness ratio; NA, not available; PPSAs, prolonged prophylaxis systemic
antimicrobials; T1, systemic antibiotics + plain cement + conventional ventilation; T2, non-systemic antibiotics + plain cement + laminar airflow; T3, systemic antibiotics + plain cement
+ laminar airflow; T4, non-systemic antibiotics + antibiotic-impregnated cement + conventional ventilation; T5, systemic antibiotics + antibiotic-impregnated cement + conventional
ventilation; T6, systemic antibiotic + antibiotic-impregnated cement + laminar airflow; T7, systemic antibiotics + antibiotic-impregnated cement + ventilation + body exhaust suit; T8,
systemic antibiotics + antibiotic-impregnated cement + laminar ventilation + body exhaust suit; THA, total hip arthroplasty; TKA, total knee arthroplasty; US$, the United States Dollars.
the extensive financial evaluation of late-occurrence SSIs. Twelve
included studies (60%) defined the time for the appearance of
SSIs within diverse follow-up intervals for trial-based studies and
time horizons for model-based studies.
Obviously, the clinical outcome depends not only on
prophylactic antibiotics which is prior to surgical procedures
but also on minimal intervention comprising limited tissue
damage, which has the effect of accelerating wound healing
(Khodakaram et al., 2016). Therefore, the other influential issues
that were identified as high-cost in the management of surgical
patients include surgical techniques, skilled surgeons, types of
diseases, and the for-profit or not-profit nature of healthcare
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Courville
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NA Day 30 NA
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et al., 2013
NA Penicillin G sodium + gentamicin: 11(11%)
Clindamycin + amikacin: 8(8%)
P value: 0.47 NA NA
*The provided percentages were the percentages within the group. CI, confident interval; ICU, intensive care unit; i.v., intravenous; LoS, length of stay; NA, not available; PPSAs,
prolonged prophylaxis systemic antimicrobials; SWI, sternal wound infection; T0, No systemic antibiotics + plain cement + conventional ventilation; T1, systemic antibiotics + plain
cement + conventional ventilation; T2, non-systemic antibiotics + plain cement + laminar airflow; T3, systemic antibiotics + plain cement + laminar airflow; T4, non-systemic antibiotics
+ antibiotic-impregnated cement + conventional ventilation; T5, systemic antibiotics + antibiotic-impregnated cement + conventional ventilation; T6, systemic antibiotic + antibiotic-
impregnated cement + laminar airflow; T7, systemic antibiotics + antibiotic-impregnated cement + ventilation + body exhaust suit; T8, systemic antibiotics + antibiotic-impregnated
cement + laminar ventilation + body exhaust suit.
system services (Ogola and Shafi, 2016; Leaper and Edmiston,
2017). The desired economic impacts of the proper use of
prophylactic antibiotics in SSIs prevention are shorter lengths
of stay, lower resistance rates, and ultimately, the reduction of
costs. Some evidence showed a positive relationship between
the infection rate and length of stay, and the reason given was
that inpatients are at a high risk of infection by nosocomial and
often antibiotic- and multi-resistant microorganisms (Pereira
et al., 2015; Al-Mousa et al., 2016; Maseda et al., 2016; Karanika
et al., 2017; Salgado Yepez et al., 2017). Costs for a day of
hospital stay and re-hospitalizations especially in the short-term
are virtually fully fixed (Roberts et al., 2009). For instance, a
prospective study with a hospital perspective included direct
medical costs by calculation based on length of hospital stay
in nosocomial infections after head and neck cancer surgery
(Penel et al., 2008). Of the included studies 9(45%) included
length of hospitalization in their evaluation. Moreover, costs
due to antimicrobial resistance indicate the secondary costs for
advanced medications to overcome the resistance rates can be
expected to eventually become variable costs (Roberts et al.,
2009). Timing for administration of prophylactic antibiotics is
essential to evaluate the clinical effectiveness, resistance, and
costs. A previous RCT in London stated that administration
of prophylactic antibiotics within 2 h prior to incision had the
lowest risk of SSIs (Classen et al., 1992). Regarding the frequency
of the drug administration, an included study showed that
prolonged prophylactic use after 24 h post-surgery did not show
any benefit in cost and SSI prevention (Lewis et al., 2016).
With regards to new antibiotics, the pricing process has
a significant influence on the calculation of the economic
outcomes, and thus bias potentially comes particularly from trial-
based economic studies that are sponsored by the pharmaceutical
industry. The industry can affect the way in which results
are reported (Bell et al., 2006; John-Baptiste and Bell, 2010).
Disclosure of either funding contributions or conflicts of interest
in all the works and the findings of each study is a recommended
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- Rectal cancer surgery
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*Adjusted mean cost in US$ at 2015-inflation rate.
MRSA, Methicillin-resistance Staphylococcus aureus.
strategy to identify potential bias (Palumbo et al., 2004). Half of
the included studies explicitly included a statement of conflict of
interest. It is essential to adjust the costs for antibiotics especially
for patented drugs that could decrease significantly in price when
the patent period expires. Only 7(35%) included studies reported
the costs of the antibiotics including the price of a single dose.
In the economic evaluation, the outcome parameters are
holistic including costs, clinical effectiveness, and utility. Hence,
a narrow or restricted perspective fosters omission of some
essential costs and outcomes. Half of the included studies did
not explicitly state the perspective, hence here may be cost
measurement omission bias (Evers et al., 2005). For both trial
and model-based studies, the societal perspective has a broader
view and its use is recommended in economic evaluation
(Jonsson, 2009). The included study by Singh et al. (2014)
showed that the societal perspective had a 10 times higher
cost compared with healthcare and payer perspectives since
not only direct costs but also productivity loss is considered
comprehensively in a societal perspective which is also referred
to as a patient’s perspective (Drummond et al., 2015). Of the
included studies only 3(15%) took into account the societal
perspective with DALY and QALY as utility units. Most of
the included studies (75%) performed CMA as the method to
analyze the costs for SSIs. Obviously, CMA was simply used and
implemented to address the costs due to the presence of SSIs
such as in two studies in cesarean section and orthopedics which
reported the median cost for SSIs at US$4,091 and US$108,782,
respectively (Olsen et al., 2008; Thakore et al., 2015). The
values were in line with the findings from the included studies
which amounted to between US$482 and US$120,989. The high
burden of post-surgical procedures when SSIs are concomitantly
present with nosocomial pneumonia is also a complication
post-surgery. The additional direct medical cost was considered
to increase from EUR19,000 for SSIs to EUR35,000 for both
post-surgical complications (Penel et al., 2008). Furthermore,
in clinical outcome measurements, there is some evidence that
systemic prophylactic antibiotics have a significant impact on
minimizing the incidence of SSIs and medical costs in high-
risk patients, especially in major surgical procedures including
oncologic surgery (Jones et al., 2014), cardiothoracic (Lador
et al., 2012), cesarean section (Smaill and Grivell, 2014), and
orthopedic surgery (Brown et al., 2004). To achieve high efficacy,
a current strategy is a prophylactic combination added locally
to the standard prophylaxis, especially in deep surgical sites, for
instance, using intra-wound vancomycin (Xiong et al., 2014) or
gentamicin (Friberg et al., 2005). A meta-analysis showed that
implantable gentamicin-collagen reduced either superficial or
deep wound infection effectively, even though the mortality rate
was not significantly different (Kowalewski et al., 2015). The use
of a local or intra-wound antibiotic as an add-on treatment can
be predicted as more effective since the site-target concentration
of antibiotics with local treatment is higher than that without
local antibiotics. In contrast, Eklund et al. (2005) stated that there
was no statistically significant difference in SSI rates between
an add-on local gentamicin group and the group without local
prophylaxis.
The scope of a cost analysis is critical when evaluating
the relevant costs and the patient’s expectations on clinical
outcomes and safety. To achieve successful treatments especially
in the use of antibiotics, antimicrobial susceptibility and
the pattern of pathogens causing SSIs should be taken into
account. Under-reported unsusceptible antibiotics in the group
of high SSI rates can potentially produce bias especially in the
interpretation of the treatment outcomes. Therefore, failure in
clinical improvement from surgical wounds should consider
the local epidemiology susceptibility of antibiotics. None of
the included studies reported on antimicrobial susceptibility.
Notably, regarding SSIs the importance of correct and early
diagnosis cannot be stressed enough. Here, microbiological
diagnostics are paramount in decisions for specific antibiotic
treatment. Treating infection in the most effective method with
the correct antibiotics is important with respect to the treatment,
but also with respect to the development of antibiotic resistance
(Dik et al., 2015). An integrated stewardship program, such
as the AID stewardship (Antibiotic, Infection Prevention, and
Diagnostic Stewardship) is crucial since it targets all different
aspects of infection management. This theragnostic approach
involves a combination between diagnostics and therapeutics
considering the interdisciplinary staff in the complexity of
infection management. The role of diagnostic stewardship
is especially gaining momentum right now to achieve a
personalized approach in infection management (Dik J. H. et al.,
2017; Dik J.-W. H. et al., 2017; Messacar et al., 2017). Therefore,
this review comprehensively takes into account all stewardship
aspects on each surgical procedure in terms of the effectiveness
of prophylactic therapeutics, diagnostics to determine SSIs
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the pathogens, patient safety, antibiotic resistance, timing of
prophylaxis, and further impact on costs.
We are aware that this review has limitations. Notably, the
study may be less representative of other important procedures
such as urological, ophthalmological, organ transplantations,
implantable devices, and dental surgery. Nearly 15% of 441
patients undergoing kidney transplantation in a hospital in the
US developed SSIs. In the 2013 annual report, almost 18,000
patients have carried out kidney transplantation procedures
(National Institutes of Health, 2015). It indicated a high number
of potential SSIs coming from the procedures and obviously a
need exists to perform an analysis on the cost and effectiveness of
the use of prophylactic antibiotics. Of 208 eligible studies, only 3
studies referred to SSIs in urology; nevertheless these studies did
not meet the further inclusion criteria. Using different definitions
to determine the infections potentially leads to underreporting
of SSIs and the location or types of SSIs, even in community
health services. Of the included studies, the only one reported
incidence of the SSIs based on the types (Emohare et al., 2014).
The reporting of updated data related to microbiological results
is fruitful, even though it may be more difficult to determine
the definite cause of SSI at particular sites of the incision from
the results. In the study, none of the included studies considered
procedures in children or pediatric surgery which has a higher
risk of SSIs and different pathogen patterns. Moreover, because
of major differences in the incidence of antibiotic resistance
between the US and Europe, outcome studies need to be
interpreted with caution. Finally, this review used the CHEC
as a rigorous method to assess the quality of the articles and
can be used as a baseline for guidelines for further economic
evaluations (Evers et al., 2015). During the work of this review,
we have followed a standard checklist from PRISMA in reporting
systematic review. The checklist is shown in Table S4.
CONCLUSIONS
Overall, we describe novel findings from reviewing the
economic evaluations of studies concerning prophylactic
antibiotic uses for SSI prevention in general surgery,
orthopedic surgery, neurosurgery, cardiothoracic surgery,
obstetric and gynecological surgery, and oncologic surgery.
Preoperative prophylactic antibiotics administered either
locally or systemically are considered in some studies and
for specific interventions at preventing SSIs. The quality
in reporting of economic evaluation indicates that the
included studies need to be improved for further research,
especially with respect to issues related to antimicrobial
susceptibility, pathogens causing SSIs, cost perspectives,
incremental analysis, and sensitivity analysis of the costs.
Notably, the valuable information in terms of cost, updated
causes of SSIs from this review can be considered in the clinical
implementation in the proper use of prophylactic antibiotics
to reduce costs and to prevent SSIs and further antimicrobial
resistance.
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